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The	last	decade	has	seen	the	development	or	renewal	of	classification	criteria	in	
sundry	rheumatic	diseases,	including	systemic	lupus	erythematosus	(SLE),[1]		
rheumatoid	arthritis,[2]	and	axial	spondyloarthritis	(axSpA).[3]	These	criteria	
seek	the	laudable	aim	of	standardising	the	populations	included	in	clinical	trials	
and	observational	cohorts	for	research	purposes.	But	to	what	extent	have	the	
benefits	of	classification	criteria	been	realised?	Have	there	been	unintended	
consequences	as	their	profile	has	grown?	And	could	we	better	use	criteria	to	
achieve	the	desired	end	of	facilitating	the	implementation	and	interpretation	of	
research	findings	to	enable	their	translation	into	clinical	practice?	
We	are	all	familiar	with	the	refrain	of	key	opinion	leaders	when	they	present	
their	update	on	the	management	of	a	disease	–	“These	are	classification	criteria,	
not	diagnostic	criteria	…”	But	how	often	have	we	heard	the	same	speaker	move	
smoothly	on	to	state,	“…	but	I	find	them	helpful	in	clinical	practice	too”?	Indeed,	
the	abstract	of	the	original	paper	describing	the	validation	and	final	selection	of	
the	classification	criteria	for	axSpA	concluded	with	the	statement	that	“The	new	
ASAS	classification	criteria	for	axial	SpA	…	may	help	rheumatologists	in	clinical	
practice	in	diagnosing	axial	SpA	in	those	with	chronic	back	pain.”	[3]	
	However,	the	dangers	of	applying	classification	criteria	to	clinical	practice	for	
the	purpose	of	diagnosis	are	easily	demonstrated.	The	criteria	are	invariably	
developed	and	validated	in	specialist	centres	where	there	is	a	high	prior	(pre-
test)		probability	of	the	disease,	and	they	are	evaluated	based	on	a	clinical	
diagnosis	of	the	disease	in	question	made	by	experts	in	that	condition,	after	
alternative	causes	or	explanations	for	the	patient’s	symptoms	have	been	
excluded.	When	the	criteria	are	applied	to	a	different	population	-	for	instance,	in	
primary	care	-	where	there	is	a	low	prior	(pre-test)		probability	of	the	disease,	
they	result	in	a	large	number	of	false	positive	diagnoses.	Take	the	example	of	
axSpA:	a	systematic	literature	review	and	meta-analysis	identified	seven	studies	
that	examined	the	ASAS	criteria’s	performance,	with	a	pooled	sensitivity	82%,	
specificity	87%	and	positive	likelihood	ratio	(LR+)	of	6.2.[4]	Applying	these	
figures	in	a	secondary	care	setting	with	a	prior	(pre-test)		probability	of	0.3	
(30%),	results	in	a	posterior	(post-test)		probability	of	0.72	(72%)	of	those	who	
fulfil	the	criteria.	However,	if	the	criteria	were	applied	in	a	low	risk	population,	
with	a	prior	(pre-test)		probability	of	0.05	(5%),	then	75%	of	the	people	fulfilling	
the	criteria	would	be	given	a	false	positive	diagnosis	(figure	1).	
This	is	not	a	theoretical	concern	that	is	without	practical	implications:	we	can	
see	the	dangers	worked	out	in	practice	in	the	literature.	For	instance,	the	authors	
of	a	study	of	chronic	low	back	pain	in	primary	care	began	with	the	flawed	
premise	that	the	new	ASAS	classification	criteria	‘will	improve	early	diagnosis’.	
They	studied	young	patients	with	chronic	low	back	pain	and	found	that	86/363	
(24%)	patients	fulfilled	the	ASAS	classification	criteria	for	axSpA.	The	authors	
concluded	that	chronic	low	back	pain	in	young	patients	is	‘frequently	caused	by	
undiagnosed	axial	SpA’.	Of	note,	only	17/86	(20%)	of	the	identified	cases	were	
HLA-B27	positive:	it	is	highly	likely	that	most	of	those	fulfilling	the	ASAS	
classification	criteria	were	false	positive	diagnoses	based	on	the	inappropriate	
use	of	the	classification	criteria.[5]	
The	pitfalls	of	the	inappropriate	use	of	classification	criteria	for	the	purpose	of	
diagnosis	are	well	known;	but	have	the	putative	benefits	of	their	use	in	research	
been	realized?	Let	us	use	axSpA	as	an	example	again:	like	most	of	the	
inflammatory	rheumatic	conditions,	axSpA	is	a	spectrum	that	ranges	from	
early/mild	to	severe/late	disease,	such	that	only	some	patients	with	severe	
disease	ultimately	exhibit	the	classical	radiographic	features	of	ankylosing	
spondylitis.	Restricting	recruitment	to	pivotal	Phase	3	studies	to	those	who	
fulfilled	the	modified	New	York	criteria	for	ankylosing	spondylitis	led	to	
approval	for	TNFi	therapy	being	restricted	to	this	population.	Recognition	of	the	
limitations	of	the	modified	New	York	criteria	were	part	of	the	driving	force	
behind	the	development	of	the	ASAS	classification	criteria	for	axSpA.	Additional	
studies	of	patients	with	non-radiographic	axSpA	were	required	by	the	FDA	
before	approval	was	granted	for	these	patients	–	but	these	are	part	of	the	
spectrum	of	the	same	condition[6]		and	it	makes	no	sense	to	require	drug	
development	programs	to	study	different	sub-populations	based	on	their	
classification	status,	rather	then	their	clinical	diagnosis.	The	tail	has	started	to	
wag	the	dog!	
Moreover,	clinicians	are	left	with	the	conundrum	of	how	to	apply	the	results	of	
clinical	studies	to	their	practice.	Using	the	fulfillment	of	classification	criteria	as	
an	inclusion	criterion	for	a	clinical	study	risks	the	unnecessary	exclusion	of	
patients	from	the	study	who	in	real	life	could	benefit	(e.g.	by	limiting	
participation	to	those	who	meet	the	modified	New	York	criteria)	or	the	
inappropriate	inclusion	of	many	patients	without	the	disease	(e.g.	if	the	ASAS	
criteria	were	used	to	identify	suitable	recruits	in	primary	care	populations).	How	
are	clinicians	to	decide	whether	the	results	of	a	study	apply	to	their	patient?	In	
clinical	practice,	we	(ought	to)	make	decisions	based	on	the	patient’s	clinical	
diagnosis	(based	on	history,	examination,	investigations,	and	the	exclusion	of	
alternative	explanations),	not	on	whether	he/she	fulfills	the	classification	criteria.		
It	follows	that	the	most	appropriate	inclusion	criterion	for	a	clinical	trial	ought	to	
be	a	clinical	diagnosis	of	sufficient	disease	activity/severity	to	warrant	the	
treatment	being	studied.	
Updated	EULAR/ACR	classification	criteria	for	SLE	have	recently	been	published.	
The	criteria	use	weighted	scores	for	different	clinical,	immunological	and	
pathological	features	in	several	domains;	the	accrual	of	10	or	more	points	leads	
to	a	classification	of	SLE.	This	creates	a	dichotomy	of	those	who	do/do	not	meet	
the	classification	criteria,	but	diagnosis	is	not	binary.	Firstly,	does	it	ensure	the	
standardization	of	a	population	of	patients	with	‘definite	SLE’?	We	know	that	the	
disease	is	heterogeneous,	and	that	ethnicity,	type	of	organ	involvement	and	
immunology	are	all	strongly	associated	with	differing	outcomes	–	patients	with	
neuropsychiatric	lupus	are	very	different	from	patients	with	predominantly	
cutaneous	disease,	even	if	both	fulfill	the	classification	criteria.	Secondly,	does	
the	dichotomy	result	in	the	exclusion	of	some	patients	with	a	clinical	diagnosis	of	
SLE	from	studies?	Without	doubt!	This	has	led	to	the	development	of	the	concept	
of	‘incomplete	lupus’	representing	patients	with	mild	or	early	disease,	and	those	
with	a	restricted	number	of	clinical	features.	These	patients	also	have	significant	
morbidity	that	requires	research	and	treatment	but	they	are	excluded	from	
studies	which	use	the	fulfillment	of	classification	criteria	as	an	entry	criterion.	
Hence	we	see	randomized	controlled	trials	being	designed	to	test	treatment	
efficacy	in	patients	defined	as	having	‘incomplete	lupus’.[7]		
Classification	criteria	for	RA	were	updated	in	2010.	These	have	been	broadly	
welcomed	as	an	improvement	(in	terms	of	sensitivity	and	applicability)	in	early	
disease.	However,	their	use	in	clinical	trials	has	led	to	some	distortion	of	the	
populations	who	have	been	studied.	For	example,	it	is	known	that	patients	with	
sero-positive	RA	have	a	worse	long	term	prognosis	than	those	with	sero-
negative	disease;	there	is	also	plentiful	evidence	that	higher	disease	activity	over	
time,	is	associated	with	poorer	outcomes.	Yet	when	we	look	at	patients	enrolled	
in	trials	in	early	RA	we	may	observe	a	paradox	–	patients	who	are	sero-negative	
have	higher	disease	activity	(e.g.	in	ARCTIC,	sero-negative	patients	had	DAS28	=	
3.9	at	baseline,	compared	to	DAS28	=	3.4	in	sero-positive	patients).[8]	The	
reason	may	be	quite	simple	–	the	presence	of	strong	positive	rheumatoid	factor	
(RF)	or	anti-citrullinated	protein	antibodies	(ACPA)	contributes	three	points	
towards	the	six	required	to	fulfill	the	classification	criteria	for	‘definite’	RA.	
Denied	these	three	points,	patients	who	are	sero-negative	must	have	higher	
disease	activity	if	they	are	to	fulfill	the	criteria	for	RA.	Put	another	way,	two	
patients	who	have	identical	clinical	features	and	acute	phase	response	may	be	
classified	differently	according	to	their	auto-antibody	status,	one	thereby	being	
eligible	for	a	study	and	the	other	being	excluded.	Now	it	may	be	that	ACPA	
positive	disease	is	fundamentally	different	from	sero-negative	disease,	but	if	that	
is	true	it	would	make	more	sense	to	include	patients	on	the	basis	of	their	ACPA	
status	rather	than	conflating	this	with	the	fulfillment	of	the	classification	criteria.	
These	examples	demonstrate	that	the	use	of	classification	criteria	in	clinical	
practice	to	make	a	diagnosis	is	inappropriate.	It	risks	over-diagnosis,	over-
referral	and	over-treatment	in	populations	with	a	low	prior	(pre-test)		
probability	of	disease.	In	research,	the	use	of	the	fulfillment	of	classification	
criteria	as	the	grounds	for	entry	to	a	clinical	trial	leads	to	the	distortion	of	the	
study	population	and	inappropriate	restrictions	on	the	label	when	drugs	are	
licensed.	How	then	can	classification	criteria	be	used	most	effectively?	They	
should	be	used	as	a	lens	through	which	the	study	population	can	be	viewed,	such	
that	different	studies	can	be	compared	and	contrasted.	The	main	entry	criterion	
for	a	clinical	trial	ought	to	be	a	clinician	diagnosis	with	sufficient	disease	activity	
(or	severity)	to	justify	the	planned	treatment.		At	first	sight,	the	proposal	to	
revert	to	using	a	clinical	diagnosis	as	an	entry	criterion	to	a	clinical	study	risks	a	
return	to	the	‘bad	old	days’	with	the	danger	that	investigators	from	different	
backgrounds	with	varying	levels	of	expertise	would	recruit	inappropriate	
patients	into	studies.	This	is	to	misunderstand	the	problem	because,	as	we	have	
shown,	a	high	prior	(pre-test)	probability	of	disease	is	a	necessary	pre-requisite	
for	the	appropriate	use	of	classification	criteria.	If	the	clinical	diagnoses	cannot	
be	trusted,	then	the	fulfilment	of	the	classification	criteria	will	not	guarantee	a	
high	posterior	probability	of	the	disease	either.	As	the	authors	of	the	
ACR/EULAR	SLE	classification	criteria	point	out,	scoring	is	a	process	that	
requires	“diligence	and	clinical	experience.”[1]	The	robustness	of	the	diagnoses	
on	a	population	level	will	be	derived	from	describing	the	cohort	in	detail,	
including	the	proportion	that	fulfill	the	relevant	classification	criteria.	This	has	
several	advantages:	(1)	it	will	help	to	avoid	imposing	an	artificial	dichotomy	on	
conditions	that	represent	a	continuous	spectrum;	(2)	if	necessary,	a	priori	sub-
group	analyses	can	be	planned	to	compare	those	who	fulfill	the	criteria	with	
those	who	don’t;	(3)	it	will	allow	nuanced	characterisation	of	research	cohorts	
(e.g.	in	SLE,	describing	the	average	number	of	points	scored,	and	in	which	
domains).	
Much	useful	work	has	been	undertaken	during	the	development	of	classification	
criteria,	and	we	should	not	‘throw	the	baby	out	with	the	bath	water’.	But	
clinicians	must	resist	the	temptation	to	use	the	criteria	in	patient	diagnosis,	and	
the	use	of	the	criteria	to	define	which	patients	are	recruited	into	clinical	trials	
needs	to	evolve.	
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Figure	1	–	nomogram	to	calculate	the	posterior	(post-test)probability	according	
to	the	prior	(pre-test)		probability	and	likelihood	ratio.	In	axSpA,	the	ASAS	
classification	criteria	have	sensitivity	82%,	specificity	87%,	and	positive	
likelihood	ratio	(LR+)	6.2:	
A.	Where	the	prior	(pre-test)	probability	=	0.3,	the	posterior	(post-test)	
probability	=	0.72	in	those	who	fulfill	the	criteria		
B.	Where	the	prior	(pre-test)	probability	=	0.05,	the	posterior	(post-test)	
probability	=	0.25	in	patients	who	fulfill	the	criteria	
	
	
	
	
